{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.5","upperLimit":"51.6","value":"29.2"},{"comment":"insufficient number of participants with events","groupId":"OG001","lowerLimit":"30.3","value":"37.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"130"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the number of months between study enrollment and death from any cause. Patients still alive at the last follow-up were censored on the date of last contact. Patients with disease progression on the Control arm were allowed to cross over to the trametinib arm. Per the protocol, the intent-to-treat OS analysis was not adjusted for crossover.","dispersionType":"95% Confidence Interval","groups":[{"description":"Investigators choice of Letrozole 2.5 mg po qd continuously, tamoxifen 20mg po bid continuously, paclitaxel 80mg/m2 IV over 1 hr on day 1q 7d, 3 wks on, 1 wk off, Pegylated Liposomal Doxorubicin 40 or 50mg/m2 IV over 1 hr on day 1 q. 28d, Topotecan 4.0mg/m2 over 30 min on day 1,8 and 15 of a 28 day cycle. For each arm, 1 cycle - 28 days","id":"OG000","title":"Arm A - Control Arm"},{"description":"Trametinib 2 mg po daily continuous treatment, For each arm, 1 cycle = 28 days","id":"OG001","title":"Arm B - Experimental Arm"}],"paramType":"MEDIAN","populationDescription":"All randomized patients","reportingStatus":"POSTED","timeFrame":"Time from study entry to time of death or date of last contact, an average of 29 months for arm A and 37 months for arm B","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}